CAMP4 Therapeutics Corp Dossier - Source-backed chat

CAMP4 Therapeutics Corp

CAMPNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.57

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $3.84Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $241M

Enterprise Value $154.6M

Shares Outstanding 68.2M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Camp4 Therapeutics Corp (NASDAQ: CAMP) is a clinical-stage biopharmaceutical company pioneering a novel class of RNA-targeting medicines designed to upregulate gene expression. By leveraging its proprietary RAP Platform, the company targets regulatory RNAs (regRNAs) to restore healthy protein levels in genetic diseases. The investment thesis is anchored on the upcoming clinical transition of its lead candidate, CMP-002, for SYNGAP1-related disorder in 2H 2026, backed by a robust cash runway extending into 2028 and a high-value strategic collaboration with GSK.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.50

Mean target$8.58

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$6.5010%

CMP-002 faces regulatory or clinical holds, delaying the Phase 1/2 trial initiation beyond 2H 2026. Early clinical data show limited therapeutic efficacy or safety concerns regarding intrathecal ASO administration. The GSK collaboration progresses slower than expected, forcing the company to raise capital under unfavorable market conditions.

Base CaseCentral scenario

$8.5860%

Matches the consensus mean

Camp4 successfully initiates the global Phase 1/2 clinical trial for CMP-002 in 2H 2026 with steady patient enrollment. Preclinical and natural history study collaborations (such as ProMMiS with CURE SYNGAP1) progress as planned. Cash reserves of $99.2M remain sufficient to fund operations into 2028, minimizing near-term dilution risks.

Bull CaseUpside scenario

$12.0030%

CMP-002 demonstrates outstanding safety, tolerability, and robust dose-dependent upregulation of SYNGAP1 protein in the Phase 1/2 trial, leading to rapid clinical proof-of-concept. GSK exercises multiple target options under the collaboration, triggering accelerated milestone payments. The RAP Platform is validated as a highly scalable engine for programmable protein upregulation, attracting further tier-1 biopharma partnerships.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Pioneering RAP Platform capable of mapping regRNAs and generating programmable ASO therapeutics for over 1,200 haploinsufficient and loss-of-function genetic diseases.
Lead candidate CMP-002 is on track for clinical entry in 2H 2026, addressing SYNGAP1-related disorder, a devastating neurodevelopmental condition with no approved disease-modifying treatments.
Strong financial position with $99.2M in cash as of Q1 2026, providing a runway into 2028.
Strategic collaboration with GSK provides validation, $17.5M upfront, and up to $440M in potential milestones plus royalties.

Key Investment Risks

Clinical-stage risk: The therapeutic approach of targeting regulatory RNAs to upregulate genes is novel and unproven in human clinical trials.
Development delays: Potential bottlenecks in global regulatory filings or patient recruitment for the rare SYNGAP1-related disorder.
Alternative splicing concerns: Scientific challenges regarding the long-term inclusion and stability of target RNA structures during brain development.

Thesis Invalidation Triggers

Failure to initiate the Phase 1/2 clinical trial of CMP-002 in SYNGAP1 patients by the end of 2026.
Severe adverse events or safety signals observed during early clinical evaluation of CMP-002.
Termination or material negative restructuring of the GSK strategic collaboration.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.